Yuichi Sakamori
Overview
Explore the profile of Yuichi Sakamori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamaji M, Ozasa H, Sakamori Y, Terada K, Yoshizawa A, Kikuchi R, et al.
J Thorac Dis
. 2024 Oct;
16(9):6094-6100.
PMID: 39444859
Background: Immune checkpoint inhibitors (ICIs) improved the long-term survival outcomes in patients with advanced non-small cell lung cancer (NSCLC), whereas the role of salvage surgery after ICIs was unknown. The...
2.
Ajimizu H, Sakamori Y
Mediastinum
. 2024 Aug;
8:44.
PMID: 39161586
Background And Objective: Thymic epithelial tumors (TETs) are rare and originate from the thymus. Thymomas and thymic carcinomas are the most common types of TETs. Of the two, thymomas tend...
3.
Yamada Y, Hamaji M, Okada H, Takahagi A, Ajimizu H, Koyasu S, et al.
Mediastinum
. 2024 Aug;
8:43.
PMID: 39161585
Thymic epithelial tumors (TETs), encompassing thymoma and thymic carcinoma, represent a rare and heterogeneous group of thoracic malignancies with varying prognoses and treatment strategies. Surgical resection is the cornerstone of...
4.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
5.
Ogimoto T, Ozasa H, Yoshida H, Nomizo T, Funazo T, Yoshida H, et al.
Oncol Lett
. 2023 Aug;
26(2):364.
PMID: 37545625
Immune checkpoint inhibitors (ICIs), such as nivolumab, play an essential role in non-small-cell lung cancer (NSCLC) treatment. Programmed death ligand-1 has been used as a predictive biomarker for the efficacy...
6.
Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y, et al.
Gen Thorac Cardiovasc Surg
. 2023 Feb;
71(9):534-541.
PMID: 36811789
Objectives: Immune checkpoint inhibitors (ICIs) are effective treatment options for patients with advanced non-small cell lung cancer (NSCLC); however, there is a dearth of data on outcomes of patients receiving...
7.
Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, et al.
Sci Rep
. 2023 Feb;
13(1):2117.
PMID: 36747076
No abstract available.
8.
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, et al.
Sci Transl Med
. 2022 Dec;
14(675):eabq0021.
PMID: 36516270
Despite the success of cancer immunotherapies such as programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed...
9.
Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, et al.
Cancer Sci
. 2022 Oct;
114(2):546-560.
PMID: 36285485
Tyrosine kinase inhibitors (TKIs) that target the ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene have shown dramatic therapeutic effects in patients with ROS1-rearranged non-small-cell lung cancer (NSCLC). Nevertheless, advanced...
10.
Hashimoto K, Ozasa H, Yoshizawa A, Yoshida H, Ogimoto T, Hosoya K, et al.
Oncol Lett
. 2022 Oct;
24(5):402.
PMID: 36276492
Immune checkpoint therapy (ICT) with nivolumab has been widely used to treat malignant pleural mesothelioma (MPM) since clinical trials confirmed its efficacy. However, only a few clinical trials have been...